Metformin Targets Glucose Metabolism in Triple Negative Breast Cancer

Metformin is the most widely administered anti-diabetic agent worldwide. In patients receiving metformin for metabolic syndrome or diabetes, it reduces the incidence and improves the survival of breast cancer (BC) patients. We have previously shown that metformin is particularly potent against tripl...

Descripción completa

Detalles Bibliográficos
Autores principales: Wahdan-Alaswad, RS, Edgerton, SM, Salem, HS, Thor, AD
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5959056/
https://www.ncbi.nlm.nih.gov/pubmed/29780974
http://dx.doi.org/10.4172/2476-2261.1000129

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5959056/
https://www.ncbi.nlm.nih.gov/pubmed/29780974
http://dx.doi.org/10.4172/2476-2261.1000129

Ejemplares similares